Cutaneous leukocytoclastic vasculitis due to erlotinib: Just an adverse event or also a putative marker of drug efficacy?

Cutaneous and Ocular Toxicology

Volumn 32, Issue 4, 2013, Pages 336-338

  Brandi, Giovanni ^a   Venturi, Michela ^b   Dika, Emi ^b   Maibach, Howard ^c   Patrizi, Annalisa ^b   Biasco, Guido ^a  

^a L and A Seràgnoli Hematology and Oncological Sciences Institute   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Adverse drug reactions; Molecular cancer treatment; Skin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; ERLOTINIB; PREDNISONE; RAPAMYCIN; ZOLEDRONIC ACID;

AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CASE REPORT; CHEMOEMBOLIZATION; CLINICAL FEATURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTOCLASTIC VASCULITIS; LIVER CELL CARCINOMA; LIVER GRAFT REJECTION; LIVER RESECTION; LIVER TRANSPLANTATION; LOW DRUG DOSE; MALE; RECURRENT DISEASE; SKIN BIOPSY; SPINE METASTASIS;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; HUMANS; LIVER NEOPLASMS; MALE; PROTEIN KINASE INHIBITORS; QUINAZOLINES; TREATMENT OUTCOME; VASCULITIS, LEUKOCYTOCLASTIC, CUTANEOUS;

EID: 84883199455     PISSN: 15569527     EISSN: 15569535     Source Type: Journal    
DOI: 10.3109/15569527.2013.780179     Document Type: Article

References (20)

1. Chung L, Fiorentino D. Cutaneous vasculitis. Orphanet encyclopedia. March 2005. Available from: Http://www.orpha.net/data/ patho/GB/uk-cutaneous- vasculitis.pdf [last accessed 11 Dec 2012
2. Su B-A, Shen W-L, Chang S-T, et al. Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case report. Oncol Lett 2012;3:1280-2
3. Takahashi Y, Ebi N, Yamaguchi O, et al. A case of cutaneous vasculitis caused by erlotinib treatment and a review of literature. Nihon Kokyuki Gakkai Zasshi 2011;49:663-6
4. Yuba T, Nagata K, Shiotsu S, et al. Henoch-schönlein purpura induced by erlotinib (Tarceva): A case report. Nihon Kokyuki Gakkai Zasshi 2010;48:81-5
5. Boeck S, Wollenberg A, Heinemann V. Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinib. Ann Oncol 2007;18:1582-3
6. Gutzmer R, Wollenberg A, Ugurel S, et al. Cutaneous side effects of new antitumor drugs: Clinical features and management. Dtsch Arztebl Int 2012;109:133-40
7. Electronic Medicines Compedium (eMC) Erlotinib. Summary of product characteristics. Available from: Http://www.medicines. org.uk/EMC/medicine/ 16781/SPC/Tarceva25mg%2c100mg and150mgFilm-CoatedTablets/#INDICATIONS [last accessed 2 Jul 2012
8. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009;27:843-50
9. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90
10. Cheng A-L, Kang Y-K, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25-34
11. Gotlib V, Khaled S, Lapko I, et al. Skin rash secondary to bevacizumab in a patient with advanced colorectal cancer and relation to response. Anticancer Drugs 2006;17:1227-9
12. Saif MW, Longo WL, Israel G. Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer. Clin Colorectal Cancer 2008;7: 144-8
13. Garcia-Navarro X, Puig L, Fernández-Figueras MT, et al. Bortezomib-associated cutaneous vasculitis. Br J Dermatol 2007;157:799-801
14. Campanati A, Berardi R, Onofri A, et al. A novel approach to manage skin toxicity caused by therapeutic agents targeting epidermal growth factor receptor. Ann Oncol 2012;23:1081-2
15. Myskowski PL, Halpern AC. Skin reactions to the new biologic anticancer drugs. Curr Opin Support Palliat Care 2009;3:294-9
16. Uchimiya H, Higashi Y, Kawai K, Kanekura T. Purpuric drug eruption with leukocytoclastic vasculitis due to gefitinib. J Dermatol 2010;37:562-4
17. Najarian DJ, Packianathan V, Zeitouni NC. Annular leukocytoclastic vasculitis associated with sorafenib administration. J Drugs Dermatol 2010;9:697-8
18. Chung NM, Gutierrez M, Turner ML. Leukocytoclastic vasculitis masquerading as hand-foot syndrome in a patient treated with sorafenib. Arch Dermatol 2006;142:1510-11
19. Yee KWL, Hymes SR, Heller L, et al. Cutaneous leukocytoclastic vasculitis in a patient with myelodysplastic syndrome after therapy with the rapamycin analogue everolimus: Case report and review of the literature. Leuk Lymphoma 2006;47: 926-9
20. Roayaie S, Schwartz JD, Sung MW, et al. Recurrence of hepatocellular carcinoma after liver transplant: Patterns and prognosis. Liver Transpl 2004;10:534-40